دورية أكاديمية
Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment.
| العنوان: | Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment. |
|---|---|
| المؤلفون: | Campos RMP; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Aguiar AFL; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Paes-Colli Y; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Trindade PMP; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Ferreira BK; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., de Melo Reis RA; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Sampaio LS; Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho (IBCCF), Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. |
| المصدر: | Frontiers in physiology [Front Physiol] 2021 Nov 30; Vol. 12, pp. 785176. Date of Electronic Publication: 2021 Nov 30 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101549006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-042X (Print) Linking ISSN: 1664042X NLM ISO Abbreviation: Front Physiol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation |
| مستخلص: | Despite the importance of pain as a warning physiological system, chronic neuropathic pain is frequently caused by damage in the nervous system, followed by persistence over a long period, even in the absence of dangerous stimuli or after healing of injuries. Chronic neuropathic pain affects hundreds of millions of adults worldwide, creating a direct impact on quality of life. This pathology has been extensively characterized concerning its cellular and molecular mechanisms, and the endocannabinoid system (eCS) is widely recognized as pivotal in the development of chronic neuropathic pain. Scientific evidence has supported that phyto-, synthetic and endocannabinoids are efficient for pain management, while strong data arise from the therapeutic use of Cannabis-derived products. The use of medicinal Cannabis products is directed toward not only relieving symptoms of chronic pain, but also improving several aspects of patients' welfare. Here, we review the involvement of eCS, along with other cellular and molecular elements, in chronic neuropathic pain pathology and how this system can be targeted for pain management. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Campos, Aguiar, Paes-Colli, Trindade, Ferreira, de Melo Reis and Sampaio.) |
| References: | Cureus. 2020 Dec 2;12(12):e11848. (PMID: 33409086) J Pain. 2019 Feb;20(2):146-160. (PMID: 30096445) Brain Struct Funct. 2013 May;218(3):733-50. (PMID: 22618437) Biochim Biophys Acta Mol Basis Dis. 2020 Jul 1;1866(7):165771. (PMID: 32201189) J Pharmacol Exp Ther. 2012 Jul;342(1):188-95. (PMID: 22514334) Br J Pharmacol. 2008 Nov;155(6):913-24. (PMID: 18695638) Pharmacol Rev. 2018 Apr;70(2):315-347. (PMID: 29500312) Exp Neurol. 2006 Aug;200(2):480-5. (PMID: 16674943) J Exp Med. 2012 Jun 4;209(6):1121-34. (PMID: 22585736) J Clin Invest. 2010 Nov;120(11):3779-87. (PMID: 21041960) Br J Anaesth. 2008 Jul;101(1):8-16. (PMID: 18417503) Nature. 1999 Jul 29;400(6743):452-7. (PMID: 10440374) Pain. 2004 May;109(1-2):124-31. (PMID: 15082134) Adv Pharmacol. 2017;80:437-475. (PMID: 28826543) Neuroscience. 2015 Aug 6;300:254-75. (PMID: 25987204) Neuropharmacology. 2006 Jun;50(7):814-23. (PMID: 16442133) Neuroscience. 2003;120(1):155-62. (PMID: 12849749) PLoS One. 2020 Jun 4;15(6):e0234176. (PMID: 32497151) J Neurosci. 2004 Sep 29;24(39):8494-9. (PMID: 15456823) Neuropharmacology. 2017 Oct;125:207-219. (PMID: 28729222) J Neurochem. 2008 Feb;104(4):1091-100. (PMID: 18028339) Trends Pharmacol Sci. 2015 May;36(5):277-96. (PMID: 25796370) Prog Neurobiol. 2011 Jan;93(1):111-24. (PMID: 21040755) J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15. (PMID: 18354058) Curr Pain Headache Rep. 2017 Jun;21(6):28. (PMID: 28432601) Neuroscience. 1998 Mar;83(2):393-411. (PMID: 9460749) J Neurosci. 2015 Apr 15;35(15):5891-903. (PMID: 25878262) Neurotherapeutics. 2015 Oct;12(4):692-8. (PMID: 26271952) J Biol Chem. 2002 Jun 28;277(26):23278-86. (PMID: 11956198) J Pain Symptom Manage. 2014 Jan;47(1):166-73. (PMID: 23742737) Biomed Res Int. 2014;2014:686908. (PMID: 25276812) Nature. 2003 Aug 14;424(6950):778-83. (PMID: 12917686) Front Neuroanat. 2014 Apr 22;8:21. (PMID: 24795573) Semin Cell Dev Biol. 2006 Oct;17(5):582-91. (PMID: 17196854) Nat Rev Neurosci. 2017 Jan 20;18(2):113. (PMID: 28704354) Eur J Pharmacol. 1997 Jan 29;319(2-3):R3-4. (PMID: 9042616) Biol Pharm Bull. 2011;34(5):774-8. (PMID: 21532172) Nat Rev Drug Discov. 2017 Aug;16(8):545-564. (PMID: 28596533) Neuropharmacology. 2009;56 Suppl 1:244-53. (PMID: 18722389) Int J Mol Sci. 2018 Mar 13;19(3):. (PMID: 29533978) Planta Med. 2016 Aug;82(13):1169-72. (PMID: 27214593) Eur Neurol. 2017;78(5-6):320-329. (PMID: 29073592) Pain. 2017 Dec;158(12):2452-2460. (PMID: 28885457) J Clin Oncol. 2006 Jul 20;24(21):3394-400. (PMID: 16849753) Curr Neuropharmacol. 2018 Jan 30;16(2):137-150. (PMID: 28440188) Nat Rev Neurol. 2020 Jan;16(1):9-29. (PMID: 31831863) Cannabis Cannabinoid Res. 2019 Sep 23;4(3):177-182. (PMID: 31579834) Eur J Pharmacol. 2012 May 5;682(1-3):62-72. (PMID: 22374260) Neurochem Res. 2005 Aug;30(8):1037-43. (PMID: 16258853) Neuroscience. 2011 Jun 16;184:183-94. (PMID: 21496475) Br J Pharmacol. 1974 Feb;50(2):299-309. (PMID: 4609532) Pharmacology. 2009;83(4):217-22. (PMID: 19204413) Pain. 2016 Nov;157(11):2582-2593. (PMID: 27589093) Biochem Pharmacol. 1973 Nov 15;22(22):2905-10. (PMID: 4202579) Br J Pharmacol. 2017 Sep;174(17):2832-2841. (PMID: 28548225) Eur J Neurosci. 2009 Jul;30(2):251-62. (PMID: 19614976) Eur J Neurosci. 2003 Jun;17(12):2750-4. (PMID: 12823482) Neuropsychopharmacology. 2020 Jun;45(7):1105-1114. (PMID: 31812152) Behav Pharmacol. 2012 Oct;23(7):722-6. (PMID: 22954646) Mol Pain. 2018 Jan-Dec;14:1744806918768970. (PMID: 29623757) Exp Cell Res. 2007 May 15;313(9):1911-20. (PMID: 17428469) Int J Clin Pharmacol Ther. 2016 Jul;54(7):498-501. (PMID: 27191771) J Pain. 2008 Mar;9(3):254-64. (PMID: 18088560) J Pharm Pharmacol. 1990 Dec;42(12):877-8. (PMID: 1983154) Mol Pain. 2017 Jan-Dec;13:1744806917724698. (PMID: 28741432) Fam Syst Health. 2014 Dec;32(4):399-407. (PMID: 25000222) Neuroscience. 2006;138(1):329-38. (PMID: 16361064) Neurosignals. 2005;14(4):166-74. (PMID: 16215299) Nat Neurosci. 2010 Oct;13(10):1265-70. (PMID: 20852626) Pain. 2021 Jul 1;162(Suppl 1):S1-S2. (PMID: 33729207) Pain. 2007 Dec 15;133(1-3):210-20. (PMID: 17997224) Gen Hosp Psychiatry. 2012 Jan-Feb;34(1):46-52. (PMID: 22001549) Neuropharmacology. 2021 Oct 1;197:108712. (PMID: 34274349) J Ethnopharmacol. 2016 Feb 17;179:22-6. (PMID: 26721216) Int Immunopharmacol. 2010 May;10(5):547-55. (PMID: 20219697) Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89. (PMID: 25747921) Pain. 2020 Sep 1;161(9):1976-1982. (PMID: 32694387) Pain. 2020 Aug;161(8):1730-1743. (PMID: 32701834) Biomolecules. 2020 Nov 19;10(11):. (PMID: 33228239) J Neurosci. 2021 Sep 1;41(35):7492-7508. (PMID: 34244365) Syst Rev. 2020 Jul 28;9(1):167. (PMID: 32723354) Pain. 2014 Apr;155(4):654-662. (PMID: 24291734) Pain. 2021 Jul 1;162(Suppl 1):S5-S25. (PMID: 33729211) J Immunol. 2011 Mar 1;186(5):3188-96. (PMID: 21278347) Front Cell Neurosci. 2013 Oct 28;7:191. (PMID: 24191146) Ther Clin Risk Manag. 2008 Feb;4(1):245-59. (PMID: 18728714) Pain Physician. 2017 Sep;20(6):E755-E796. (PMID: 28934780) J Peripher Nerv Syst. 2006 Sep;11(3):262-71. (PMID: 16930289) J Ethnopharmacol. 1991 Aug;34(1):43-8. (PMID: 1753786) Pain Ther. 2017 Dec;6(Suppl 1):25-33. (PMID: 29178034) Br J Pharmacol. 1972 Jun;45(2):375-7. (PMID: 5048656) BMJ. 2008 Jan 26;336(7637):199-201. (PMID: 18182416) Neuron. 2015 Mar 18;85(6):1289-304. (PMID: 25789756) Pharmacol Rev. 2002 Jun;54(2):161-202. (PMID: 12037135) Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3300-11. (PMID: 23108548) Br J Pharmacol. 2001 Jun;133(4):586-94. (PMID: 11399676) Brain Behav Immun. 2015 Oct;49:233-45. (PMID: 26086345) Arthritis Res Ther. 2005;7(5):R1046-51. (PMID: 16207320) Nature. 1999 Apr 1;398(6726):436-41. (PMID: 10201375) Mol Pharmacol. 2009 Apr;75(4):965-72. (PMID: 19171674) Front Pharmacol. 2015 Feb 05;6:6. (PMID: 25698968) Br J Anaesth. 2019 Aug;123(2):e249-e253. (PMID: 30929760) Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20. (PMID: 24210682) Anesthesiology. 2007 Apr;106(4):787-94. (PMID: 17413917) J Pain Res. 2019 May 20;12:1577-1604. (PMID: 31190969) Nat Commun. 2016 Jun 28;7:12029. (PMID: 27349690) Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9099-104. (PMID: 18574142) Eur J Neurosci. 2010 Jan;31(2):225-37. (PMID: 20074214) J Neurosci. 1996 Jul 15;16(14):4322-34. (PMID: 8699243) J Comp Neurol. 1952 Jun;96(3):414-95. (PMID: 14946260) Pharmacol Res. 2013 Jan;67(1):94-109. (PMID: 23127915) Br J Pharmacol. 2007 Nov;152(5):765-77. (PMID: 17572696) Korean J Anesthesiol. 2015 Jun;68(3):311. (PMID: 26045939) Mol Cell Neurosci. 2000 Jun;15(6):510-21. (PMID: 10860578) J Ethnopharmacol. 2018 Dec 5;227:300-315. (PMID: 30205181) Neuroscience. 2002;110(4):755-64. (PMID: 11934482) Pain Res Manag. 2014 Nov-Dec;19(6):328-35. (PMID: 25479151) J Neurosci. 2003 Apr 1;23(7):2899-910. (PMID: 12684477) Anesthesiology. 2008 Apr;108(4):722-34. (PMID: 18362605) Phytother Res. 2008 Aug;22(8):1017-24. (PMID: 18618522) Integr Med Res. 2018 Jun;7(2):159-167. (PMID: 29984177) BMJ. 2014 Feb 05;348:f7656. (PMID: 24500412) J Neurosci. 2002 Aug 1;22(15):6724-31. (PMID: 12151551) Clin Exp Pharmacol Physiol. 2015 Mar;42(3):246-55. (PMID: 25430877) Int J Mol Sci. 2020 Apr 16;21(8):. (PMID: 32316328) Nat Rev Dis Primers. 2017 Feb 16;3:17002. (PMID: 28205574) Mol Med Rep. 2017 Jan;15(1):89-96. (PMID: 27959414) Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. (PMID: 24836296) Lancet Neurol. 2015 Feb;14(2):162-73. (PMID: 25575710) Clin Pharmacol Ther. 1980 Jul;28(1):115-20. (PMID: 7389248) Eur J Pharmacol. 2004 May 3;491(2-3):137-48. (PMID: 15140630) Eur J Pharmacol. 2008 Apr 14;584(1):78-86. (PMID: 18313663) J Neurol. 2013 Apr;260(4):984-97. (PMID: 23180178) Eur J Neurol. 2010 Sep;17(9):1113-e88. (PMID: 20402746) Br J Pharmacol. 2001 Oct;134(4):845-52. (PMID: 11606325) J Neurosci. 2001 Dec 1;21(23):9506-18. (PMID: 11717385) J Neuroinflammation. 2017 Sep 12;14(1):185. (PMID: 28899427) Eur J Pharmacol. 2008 Mar 31;583(1):56-61. (PMID: 18279850) Eur J Pain. 2013 Nov;17(10):1547-57. (PMID: 23720357) Neurol Sci. 2016 Feb;37(2):235-42. (PMID: 26474875) J Pharmacol Exp Ther. 1996 Sep;278(3):989-99. (PMID: 8819477) Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14. (PMID: 20194146) Brain Res. 1999 Mar 20;822(1-2):17-25. (PMID: 10082879) Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182. (PMID: 29513392) |
| فهرسة مساهمة: | Keywords: THC; cannabidiol; cannabis; endocannabinoid; neuropathic pain |
| تواريخ الأحداث: | Date Created: 20211217 Latest Revision: 20211218 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8669747 |
| DOI: | 10.3389/fphys.2021.785176 |
| PMID: | 34916962 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-042X |
|---|---|
| DOI: | 10.3389/fphys.2021.785176 |